EUCTR2007-002155-17-GB进行中（未招募）1 期
A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cells
GlaxoSmithKline Research and Development Limited0 个研究点目标入组 0 人开始时间: 2007年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signed written informed consent
- •2. Female patients, age = 18 years
- •3. Histologically confirmed diagnosis of HER-2 negative (i.e. no gene amplification by FISH or IHC 2+ and no amplification by FISH or IHC 0/1+) infiltrating primary breast cancer.
- •4. Evidence of EGFR positive circulating tumour cells or HER-2 positive (=50% CTCs or FISH positive) in a peripheral blood sample taken at screening visit.
- •5. Metastatic disease with at least one measurable lesion as per RECIST criteria classification
- •6. No brain metastasis requiring local therapy. Stable or asymptomatic subjects are allowed.
- •7. Availability of tumour block or at least six unstained 4 µm sections of the primary
- •tumour to be sent to the central lab after eligibility confirmation for HER-2 central testing by FISH.
- •8. Eastern Cooperative Oncology Group (ECOG) score for performance status 0 to 3
- •9. Life expectancy > 12 weeks
- •10. Adequate baseline haematologic, hepatic and renal function at screening visit.
- •11. Normal left ventricular ejection fraction (LVEF) by echocardiogram or MUGA.
- •12. Negative serum pregnancy test (only in childbearing potential female)
- •13. Patients with reproductive potential needs consistent and correct use of adequate non-hormonal methods of birth control (barrier methods or intrauterine device)
- •14. Previous treatment with anthracyclines and/or taxanes in the neo-adjuvant,
- •adjuvant or advanced setting
- •15. At least one line of treatment for metastatic disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any unstable systemic disease including active infections, significant cardiovascular disease, as well as myocardial infarction within the previous year, any significant hepatic (current active hepatic or biliary disease [with exception of patients with Gilbert's syndrome, asymtomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment]), renal or metabolic disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of study medication or that might affect the interpretation of the results or render the patient at high risk from treatment complications.
- •2. Pregnant or lactating women
- •3. Dementia, altered mental status, or any psychiatric condition that could prohibit the understanding or rendering of informed consent
- •4. Lack of physical integrity of the upper gastrointestinal (GI) tract, poor absorption
- •of the GI tract or inability to take oral medication
- •5. Other co-existing malignancy or malignancies within the last 5 years with the
- •exception of basal cell carcinoma or in-situ carcinoma
- •6. Concurrent anti-cancer therapies (chemo or hormonal therapy) other than study drug
- •7. Concurrent treatment with an investigational agent or participation in any investigational drug study within 4 weeks preceding treatment start
- •8. Concurrent radiotherapy to the only target lesion. Concurrent bisphosphonates are allowed as long as this therapy has started before patient receives study medication.
- •9. Previous treatment with anti HER-2 or anti-EGFR therapies
- •10. Protocol specified treatment regimens that would be inappropriate for the
- •management of the subject (See also concomitant medication Section 7.9).
研究者
相似试验
进行中（未招募）
不适用
A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cells - NDEUCTR2007-002155-17-ITGlaxoSmithKline Research & Development Limited62
招募中
1 期
The study is a Phase 2, open-label, multicenter study to determine the efficacy and safety of Luspatercept (ACE-536) in adults with congenital dyserythropoietic anemia type II (CDA II).Congenital Dyserythropoietic Anemia type II (CDAII)MedDRA version: 21.1Level: PTClassification code 10081457Term: Congenital dyserythropoietic anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-005736-30-ITFOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia40
进行中（未招募）
不适用
A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in ß-thalassemia patients with severe cardiac iron overload - DFX AutonomyEUCTR2009-018091-34-GRovartis (Hellas) S.A.C.I52
进行中（未招募）
1 期
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous CarcinomaCTIS2023-507324-23-00K-Group Beta Inc.120
进行中（未招募）
1 期
A multicenter phase II open label study to evaluate efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanomaEUCTR2016-002114-50-SESahlgrenska University Hospital29